Bavarian Nordic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

23.11.16	Bavarian Nordic Completes Enrollment of Phase 3 Non-inferiority Study of IMVAMUNE® Smallpox Vaccine (GlobeNewswire)
23.11.16	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
10.11.16	Bavarian Nordic to Present at Jefferies 2016 London Healthcare Conference (GlobeNewswire)
09.11.16	Bavarian Nordic Announces Interim Results for the First Nine Months of 2016 (GlobeNewswire)
01.11.16	Bavarian Nordic to Host Third Quarter 2016 Results Conference Call (GlobeNewswire)
18.10.16	Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine (GlobeNewswire)
10.10.16	Bavarian Nordic Announces Initiation of Phase 2 Combination Trial of PROSTVAC and Ipilimumab in Patients with Localized Prostate Cancer (GlobeNewswire)
29.09.16	Bavarian Nordic Announces Presentation of Phase 1 Data for its RSV Vaccine at International RSV Symposium (GlobeNewswire)
28.09.16	Bavarian Nordic Appoints Christopher Heery, M.D., as Chief Medical Officer (GlobeNewswire)
13.09.16	Bavarian Nordic Issues Financial Calendar for 2017 (GlobeNewswire)
12.09.16	Bavarian Nordic Announces that Janssen has completed a Submission for Emergency Use Assessment and Listing for its Ebola Vaccine Regimen to the World Health Organization (GlobeNewswire)
17.08.16	Bavarian Nordic Announces First Half 2016 Results (GlobeNewswire)
15.08.16	Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study (GlobeNewswire)
27.07.16	Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine (GlobeNewswire)
15.06.16	Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government (GlobeNewswire)
02.06.16	Bavarian Nordic to Present at Jefferies 2016 Healthcare Conference in New York (GlobeNewswire)
26.05.16	Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations (GlobeNewswire)
23.05.16	Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations (GlobeNewswire)
19.05.16	Bavarian Nordic Announces USD 100 Million Supply Contract for IMVAMUNE Smallpox Vaccine with the U.S. Government (GlobeNewswire)
13.05.16	Bavarian Nordic Announces Interim Results for the First Three Months of 2016 (GlobeNewswire)
09.05.16	Bavarian Nordic to Host First Quarter 2016 Results Conference Call (GlobeNewswire)
19.04.16	Bavarian Nordic Applauds Announcement of Positive Data for Ebola Vaccine Regimen Published in JAMA (GlobeNewswire)
21.03.16	Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise (GlobeNewswire)
07.03.16	Bavarian Nordic Awards Restricted Stock Units to Executive Management (GlobeNewswire)
07.03.16	Bavarian Nordic Announces Annual Report 2015 (GlobeNewswire)
22.02.16	Bavarian Nordic Announces New Date for Publication of its 2015 Annual Report (GlobeNewswire)
04.02.16	Bavarian Nordic Enters Research Collaboration to Develop MRSA Vaccine (GlobeNewswire)
05.01.16	Bavarian Nordic Announces 3:1 Effective Split of American Depositary Shares (GlobeNewswire)
04.01.16	Bavarian Nordic Files Registration Statement for Proposed Initial Public Offering of ADSs in the United States (GlobeNewswire)
18.12.15	Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine (GlobeNewswire)
11.11.15	Bavarian Nordic to Present at Jefferies 2015 Global Healthcare Conference in London (GlobeNewswire)
03.11.15	Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancers (GlobeNewswire)
03.11.15	Bavarian Nordic Announces Interim Results for the First Nine Months of 2015 (GlobeNewswire)
28.10.15	Bavarian Nordic Announces Expansion of IMVAMUNE® Orders from Canadian Government (GlobeNewswire)
27.10.15	Bavarian Nordic to Host Third Quarter 2015 Results Conference Call (GlobeNewswire)
09.10.15	Bavarian Nordic Announces Initiation of Safety and Immunogenicity Study of Ebola Vaccine Regimen in Sierra Leone (GlobeNewswire)
14.09.15	Bavarian Nordic Receives Contract Valued at USD 9 Million from Janssen as part of Advanced Development of Prime-Boost Ebola Vaccine Regimen (GlobeNewswire)
11.09.15	Bavarian Nordic issues Financial Calendar for 2016 (GlobeNewswire)
25.08.15	Bavarian Nordic Announces First Half 2015 Results (GlobeNewswire)
19.08.15	Bavarian Nordic to Host First Half 2015 Results Conference Call (GlobeNewswire)
18.08.15	Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN® in Respiratory Syncitial Virus (RSV) (GlobeNewswire)
24.07.15	Bavarian Nordic Announces Initiation of NCI-sponsored Phase 2 Study of PROSTVAC in Patients with Localized Prostate Cancer (GlobeNewswire)
15.07.15	Bavarian Nordic Announces that the Oxford Vaccines Group has Initiated a Phase 2 Study of the Ebola Prime-Boost Vaccine Regimen Combining MVA-BN® Filo and Janssen's AdVac® Technology (GlobeNewswire)
07.07.15	Bavarian Nordic Receives Order for IMVAMUNE® Smallpox Vaccine from the U.S. Government Valued at USD 133 Million (GlobeNewswire)
30.06.15	Bavarian Nordic Announces Option Exercise by U.S. Government for Development of Filovirus Vaccine (GlobeNewswire)
28.05.15	Bavarian Nordic to Present at Jefferies 2015 Global Healthcare Conference in New York (GlobeNewswire)
21.05.15	Members of the management and the board increase their share holdings in Bavarian Nordic A/S (GlobeNewswire)
18.05.15	Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants (GlobeNewswire)
13.05.15	Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE® Smallpox Vaccine (GlobeNewswire)
12.05.15	Bavarian Nordic Announces Presentation of Preliminary Phase 1 Results for the Ebola Prime-Boost Vaccine Regimen of MVA-BN® Filo and Janssen's AdVac® technology (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.08.24		Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen
22.08.24		Ausblick: Bavarian Nordic legt Quartalsergebnis vor
20.08.24		Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an
23.08.22		Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

22.08.24

Bavarian Nordic-Aktie im Rally-Modus: Bavarian Nordic übertrifft Erwartungen um Längen

22.08.24

Ausblick: Bavarian Nordic legt Quartalsergebnis vor

20.08.24

Bavarian Nordic-Aktie dreht ins Minus: Produktion von Mpox-Impfstoff wird gesteigert - Halbjahreszahlen stehen an

23.08.22

Ausblick: Bavarian Nordic gewährt Anlegern Blick in die Bücher

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bavarian Nordic A/S

Aktien Top/Flop

Bavarian Nordic Peer Group Nachrichten

Meistgelesene Nachrichten